[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5y3Eg4xp6xDgw5N32G4IgX_6p9oJanpZG0uQsK83_KU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"UPECLIN HC FM Botucatu Unesp",[4],64,false,3,4,9907,1,49,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"HIV Infections",5,{"name":18,"count":8},"Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted",{"name":20,"count":21},"Patients in Good Health",2,{"name":23,"count":21},"Chronic Obstructive Pulmonary Disease",{"name":25,"count":21},"Covid19",{"name":27,"count":21},"Stroke",{"name":29,"count":21},"Varicose Veins",{"name":31,"count":21},"Telangiectasis",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06326203","Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia","2028-03-31","CELULAS TRONCO",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,70,106,128,154,181,199,224,245,271,297,315,340,369,387,413,431,456,481,507],{"intervention":37,"totalTrials":11,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":64,"PHASE4":66,"NA":68},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":11,"soonestReadout":36},[55],{"nctId":34,"briefTitle":35,"status":56,"phases":57,"primaryCompletion":36,"completion":36,"start":58,"enrollment":59,"conditions":60,"interventions":63},"NOT_YET_RECRUITING",[40,41],"2026-06-01",40,[61,62],"Peripheral Arterial Disease","Leg Ulcer",[37],{"trials":65,"activeCount":50},[],{"trials":67,"activeCount":50},[],{"trials":69,"activeCount":50},[],{"intervention":71,"totalTrials":21,"cells":72},"Glucose",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":104},{"trials":74,"activeCount":50},[],{"trials":76,"activeCount":50},[],{"trials":78,"activeCount":50},[],{"trials":80,"activeCount":50},[],{"trials":82,"activeCount":50},[83,95],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":93},"NCT02657252","Polidocanol Versus Glucose Treatment of Telangiectasia Trial","COMPLETED",[43],"2016-09","2016-11","2015-01",115,[29,31],[71,94],"Polidocanol with Glucose",{"nctId":96,"briefTitle":97,"status":86,"phases":98,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":103},"NCT02054325","Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins",[43],"2014-12","2012-09",106,[29],[94,71],{"trials":105,"activeCount":50},[],{"intervention":94,"totalTrials":21,"cells":107},{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":126},{"trials":109,"activeCount":50},[],{"trials":111,"activeCount":50},[],{"trials":113,"activeCount":50},[],{"trials":115,"activeCount":50},[],{"trials":117,"activeCount":50},[118,122],{"nctId":84,"briefTitle":85,"status":86,"phases":119,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":120,"interventions":121},[43],[29,31],[71,94],{"nctId":96,"briefTitle":97,"status":86,"phases":123,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":124,"interventions":125},[43],[29],[94,71],{"trials":127,"activeCount":50},[],{"intervention":129,"totalTrials":11,"cells":130},"Comparison of two anesthetic drugs",{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":152},{"trials":132,"activeCount":50},[],{"trials":134,"activeCount":50},[],{"trials":136,"activeCount":50},[],{"trials":138,"activeCount":50},[],{"trials":140,"activeCount":50},[141],{"nctId":142,"briefTitle":143,"status":86,"phases":144,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":151},"NCT00854178","Toxicogenomic and Immunocytotoxic Effects of Propofol and Isoflurane Anesthetics in Patients Undergoing Elective Surgery",[43],"2009-12","2008-03",26,[20,149,150],"Types of General Anesthesia","DNA Damage",[129],{"trials":153,"activeCount":50},[],{"intervention":155,"totalTrials":11,"cells":156},"Amoxycillin\u002Fclavulanic acid",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":179},{"trials":158,"activeCount":50},[],{"trials":160,"activeCount":50},[],{"trials":162,"activeCount":50},[],{"trials":164,"activeCount":50},[],{"trials":166,"activeCount":50},[167],{"nctId":168,"briefTitle":169,"status":86,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":177},"NCT01166932","Comparison Between Amoxycillin\u002FClavulanic Acid and Oxacillin\u002FCeftriaxone for Community Acquired-pneumonia",[43],"2007-04","2009-04","2005-04",104,[176],"Community-Acquired Pneumonia",[155,178],"ceftriaxone\u002Foxacillin",{"trials":180,"activeCount":50},[],{"intervention":178,"totalTrials":11,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":197},{"trials":184,"activeCount":50},[],{"trials":186,"activeCount":50},[],{"trials":188,"activeCount":50},[],{"trials":190,"activeCount":50},[],{"trials":192,"activeCount":50},[193],{"nctId":168,"briefTitle":169,"status":86,"phases":194,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":195,"interventions":196},[43],[176],[155,178],{"trials":198,"activeCount":50},[],{"intervention":200,"totalTrials":11,"cells":201},"First-line Antiretroviral Therapy",{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":210,"NA":222},{"trials":203,"activeCount":50},[],{"trials":205,"activeCount":50},[],{"trials":207,"activeCount":50},[],{"trials":209,"activeCount":50},[],{"trials":211,"activeCount":50},[212],{"nctId":213,"briefTitle":214,"status":215,"phases":216,"primaryCompletion":145,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":221},"NCT01049685","Lopinavir\u002FRitonavir or Efavirenz as First-line Antiretroviral Therapy","UNKNOWN",[43],"2010-03","2006-08",36,[15],[200],{"trials":223,"activeCount":50},[],{"intervention":225,"totalTrials":11,"cells":226},"Propofol and isoflurane",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":243},{"trials":228,"activeCount":50},[],{"trials":230,"activeCount":50},[],{"trials":232,"activeCount":50},[],{"trials":234,"activeCount":50},[],{"trials":236,"activeCount":50},[237],{"nctId":238,"briefTitle":239,"status":86,"phases":240,"primaryCompletion":145,"completion":145,"start":146,"enrollment":59,"conditions":241,"interventions":242},"NCT01111227","Inflammatory Cytokines Profile in Individuals Subjected to Surgical Procedures Using Propofol or Isoflurane",[43],[20],[225],{"trials":244,"activeCount":50},[],{"intervention":246,"totalTrials":11,"cells":247},"Spironolactone",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":269},{"trials":249,"activeCount":50},[],{"trials":251,"activeCount":50},[],{"trials":253,"activeCount":50},[],{"trials":255,"activeCount":50},[],{"trials":257,"activeCount":50},[258],{"nctId":259,"briefTitle":260,"status":215,"phases":261,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT01128101","Effects of Spironolactone in Dialysis",[43],"2012-12","2013-12","2011-03",60,[267],"Renal Failure",[246],{"trials":270,"activeCount":50},[],{"intervention":272,"totalTrials":11,"cells":273},"inhaled beclametasone",{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":291,"PHASE4":293,"NA":295},{"trials":275,"activeCount":50},[],{"trials":277,"activeCount":50},[],{"trials":279,"activeCount":50},[280],{"nctId":281,"briefTitle":282,"status":86,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":289},"NCT04937543","Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19",[41],"2021-10-30","2022-05-20","2021-06-28",50,[25],[272,290],"Inahaled beclomethasone \u002F formoterol \u002F glycopyrronium",{"trials":292,"activeCount":50},[],{"trials":294,"activeCount":50},[],{"trials":296,"activeCount":50},[],{"intervention":290,"totalTrials":11,"cells":298},{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":309,"PHASE4":311,"NA":313},{"trials":300,"activeCount":50},[],{"trials":302,"activeCount":50},[],{"trials":304,"activeCount":50},[305],{"nctId":281,"briefTitle":282,"status":86,"phases":306,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":307,"interventions":308},[41],[25],[272,290],{"trials":310,"activeCount":50},[],{"trials":312,"activeCount":50},[],{"trials":314,"activeCount":50},[],{"intervention":316,"totalTrials":11,"cells":317},"Heparin sodium",{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":319,"activeCount":50},[],{"trials":321,"activeCount":50},[],{"trials":323,"activeCount":50},[324],{"nctId":325,"briefTitle":326,"status":86,"phases":327,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":333},"NCT04743011","Enriched Heparin Anti COVID-19 Trial",[40,41],"2021-11-30","2021-12-31","2021-06-01",27,[25],[316],{"trials":335,"activeCount":50},[],{"trials":337,"activeCount":50},[],{"trials":339,"activeCount":50},[],{"intervention":341,"totalTrials":11,"cells":342},"Erythromycin",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":344,"activeCount":50},[],{"trials":346,"activeCount":50},[],{"trials":348,"activeCount":50},[],{"trials":350,"activeCount":50},[],{"trials":352,"activeCount":50},[],{"trials":354,"activeCount":50},[355],{"nctId":356,"briefTitle":357,"status":215,"phases":358,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":367},"NCT01097811","Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy",[44],"2010-06","2010-12","2008-06",20,[364,365,366],"Hepatic Encephalopathy","Hypertension, Portal","Liver Cirrhosis",[341,368],"Neomycin",{"intervention":368,"totalTrials":11,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":372,"activeCount":50},[],{"trials":374,"activeCount":50},[],{"trials":376,"activeCount":50},[],{"trials":378,"activeCount":50},[],{"trials":380,"activeCount":50},[],{"trials":382,"activeCount":50},[383],{"nctId":356,"briefTitle":357,"status":215,"phases":384,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":385,"interventions":386},[44],[364,365,366],[341,368],{"intervention":388,"totalTrials":11,"cells":389},"Stem cells stimulation",{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":398,"NA":400},{"trials":391,"activeCount":50},[],{"trials":393,"activeCount":50},[],{"trials":395,"activeCount":50},[],{"trials":397,"activeCount":50},[],{"trials":399,"activeCount":50},[],{"trials":401,"activeCount":50},[402],{"nctId":403,"briefTitle":404,"status":86,"phases":405,"primaryCompletion":406,"completion":407,"start":408,"enrollment":9,"conditions":409,"interventions":411},"NCT01110252","Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease",[44],"2010-10","2011-11","2009-05",[23,410],"Pulmonary Emphysema",[388,412],"stem cells",{"intervention":412,"totalTrials":11,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":416,"activeCount":50},[],{"trials":418,"activeCount":50},[],{"trials":420,"activeCount":50},[],{"trials":422,"activeCount":50},[],{"trials":424,"activeCount":50},[],{"trials":426,"activeCount":50},[427],{"nctId":403,"briefTitle":404,"status":86,"phases":428,"primaryCompletion":406,"completion":407,"start":408,"enrollment":9,"conditions":429,"interventions":430},[44],[23,410],[388,412],{"intervention":432,"totalTrials":11,"cells":433},"pegylated-interferon, conventional-interferon, ribavirin",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":444},{"trials":435,"activeCount":50},[],{"trials":437,"activeCount":50},[],{"trials":439,"activeCount":50},[],{"trials":441,"activeCount":50},[],{"trials":443,"activeCount":50},[],{"trials":445,"activeCount":50},[446],{"nctId":447,"briefTitle":448,"status":86,"phases":449,"primaryCompletion":450,"completion":451,"start":452,"enrollment":453,"conditions":454,"interventions":455},"NCT00514111","Factors Associated to Success of Hepatitis C Therapy",[],"2008-07","2008-12","2007-08",100,[18],[432],{"intervention":457,"totalTrials":11,"cells":458},"IPAQ",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":460,"activeCount":50},[],{"trials":462,"activeCount":50},[],{"trials":464,"activeCount":50},[],{"trials":466,"activeCount":50},[],{"trials":468,"activeCount":50},[],{"trials":470,"activeCount":50},[471],{"nctId":472,"briefTitle":473,"status":86,"phases":474,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT00517088","Level of Physical Activities in Patients Before and After Breast Cancer Treatment",[44],"2007-03","2006-05",2007,[479],"Breast Cancer",[457],{"intervention":482,"totalTrials":11,"cells":483},"ropivacaine",{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":485,"activeCount":50},[],{"trials":487,"activeCount":50},[],{"trials":489,"activeCount":50},[],{"trials":491,"activeCount":50},[],{"trials":493,"activeCount":50},[],{"trials":495,"activeCount":50},[496],{"nctId":497,"briefTitle":498,"status":86,"phases":499,"primaryCompletion":500,"completion":501,"start":500,"enrollment":502,"conditions":503,"interventions":505},"NCT00626977","Labor Analgesia With Ropivacaine and Clonidine",[],"2000-05","2001-12",32,[504],"Labor Pain",[482,506],"ropivacaine and clonidine",{"intervention":506,"totalTrials":11,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":510,"activeCount":50},[],{"trials":512,"activeCount":50},[],{"trials":514,"activeCount":50},[],{"trials":516,"activeCount":50},[],{"trials":518,"activeCount":50},[],{"trials":520,"activeCount":50},[521],{"nctId":497,"briefTitle":498,"status":86,"phases":522,"primaryCompletion":500,"completion":501,"start":500,"enrollment":502,"conditions":523,"interventions":524},[],[504],[482,506]]